Overview

Levetiracetam Treatment in Adult Subjects With Parkinson's Disease Experiencing Troublesome Dyskinesias

Status:
Completed
Trial end date:
2004-11-01
Target enrollment:
Participant gender:
Summary
This is a 41-week trial composed of two consecutive parts (Part A, 14 weeks and optional Part B, 27 weeks) to evaluate the efficacy of levetiracetam in controlling levodopa induced dyskinesias in adults with Idiopathic Parkinson's Disease, without negative impact on the benefit on the motor function of the antiparkinsonian treatment.
Phase:
Phase 2
Details
Lead Sponsor:
UCB Pharma
Treatments:
Etiracetam
Levetiracetam
Levodopa
Piracetam